Neogenomics INC Form 4 insider transactions

Greg D Aunan, Chief Accounting Officer of Neogenomics Inc, sold 20,000 shares of common stock on August 4, 2026 for $16.07 per share.

Carolyn S. Starrett, a Director at NEOGENOMICS INC, reported the acquisition of stock options and restricted stock units on June 23, 2026.

Director Lynn A. Tetrault of Neogenomics Inc. has reported transactions involving common stock and stock options, indicating a shift in beneficial ownership.

Neogenomics Inc. Director Lynn Tetrault reported a transaction involving the acquisition of 5,307 shares of common stock.

Director John P. Kenny acquired 5,893 shares of NeoGenomics common stock through the vesting of restricted stock units.

Director Felicia Williams exercised restricted stock units and received new equity grants in NeoGenomics Inc.

Director Lynn Tetrault acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.

Director David Brian Perez acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.

Director Michael Kelly acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units and received new equity grants.

Director Stephen M. Kanovsky acquired 23,077 shares of NeoGenomics common stock via RSU vesting and received new equity grants.

Director Neil Gunn acquired 23,077 shares of NeoGenomics common stock through the vesting of restricted stock units.

Director Marjorie Green acquired 22,964 shares of NeoGenomics common stock through the vesting of restricted stock units.

Alicia C. Olivo, EVP, GC & Business Development at Neogenomics Inc., reported transactions involving stock options and restricted stock units on May 11, 2026.

Greg Aunan, Chief Accounting Officer at NeoGenomics Inc., reported transactions involving common stock, restricted stock units, and stock options.

Neogenomics Inc. executive Alicia C. Olivo reported transactions involving stock options, performance stock units, and restricted stock units.

Warren Stone, President & COO of Neogenomics Inc., reported transactions involving stock options, restricted stock units, and performance stock units on May 2, 2026.

Neogenomics Inc. reports changes in beneficial ownership for its President & Chief Operating Officer, Warren Stone, involving stock options and restricted stock units.

NEOGENOMICS INC. CEO Anthony P. Zook has reported transactions involving restricted stock units and stock options, detailing grants and vesting schedules.

Neogenomics' Chief Accounting Officer, Greg D. Aunan, was granted new stock options and restricted stock units as part of his compensation.

Alicia C. Olivo, EVP, GC & Business Development at NEOGENOMICS INC, reported significant new equity grants and existing beneficial ownership in a recent SEC Form 4 filing.

Neogenomics President & COO Warren Stone reported significant new equity grants, including stock options and restricted stock units, alongside existing holdings.

NEOGENOMICS CEO Anthony P. Zook was granted 675,676 stock options and 406,918 restricted stock units effective March 1, 2026, as part of his compensation.

NeoGenomics CFO Jeffrey Scott Sherman reported routine equity transactions, including RSU vesting and tax-related dispositions, as part of his compensation plan.

NeoGenomics' President and Chief Operating Officer, Warren Stone, reported scheduled equity awards vesting and associated tax-related share dispositions.

Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics Inc., reported recent vesting of restricted stock units and associated tax-related dispositions, alongside an updated overview of her derivative holdings.

NeoGenomics Chief Accounting Officer Greg D. Aunan reported the exercise of restricted stock units and subsequent tax-related share disposition, adjusting his direct beneficial ownership.

Neogenomics' President and Chief Operating Officer, Warren Stone, reported the sale of 22,128 shares of common stock and detailed his extensive equity holdings, including various stock options and restricted units.

NeoGenomics President & COO Warren Stone reported the vesting of restricted stock units and subsequent tax-related share disposition, alongside details of his extensive derivative holdings.

Alicia C. Olivo, EVP, GC & Business Development at NeoGenomics Inc., reported the vesting of restricted stock units and related tax-driven share dispositions, alongside various stock option and performance unit holdings.

NEOGENOMICS Director John P. Kenny was granted 4,171 stock options and 5,893 restricted stock units on January 1, 2026.